Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Rodallec

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Scientific Reports|March 7, 2020
Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on NanoparticlesA Rodallec, C Franco, S Robert, et al.
The Journal of Antimicrobial Chemotherapy|May 28, 2016
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combinationS Lambert-Niclot, C Allavena, M Grude, et al.
Medecine Et Maladies Infectieuses|December 26, 2018
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)C Allavena, C Volteau, E André-Garnier, et al.
The Journal of Antimicrobial Chemotherapy|May 3, 2018
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)S Lambert-Niclot, M Grude, M L Chaix, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Scientific Reports|March 7, 2020
Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on NanoparticlesA Rodallec, C Franco, S Robert, et al.
The Journal of Antimicrobial Chemotherapy|May 28, 2016
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combinationS Lambert-Niclot, C Allavena, M Grude, et al.
Medecine Et Maladies Infectieuses|December 26, 2018
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)C Allavena, C Volteau, E André-Garnier, et al.
The Journal of Antimicrobial Chemotherapy|May 3, 2018
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)S Lambert-Niclot, M Grude, M L Chaix, et al.
Pageof 2